Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial

Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial

We conducted a dose-finding phase 2 study of the HilleVax bivalent virus-like particle (VLP) vaccine candidate (HIL-214) in two cohorts of children, 6–≤12 months and 1–≤4 years of age (N = 120 per cohort), in Panama and Colombia (ClinicalTrials.gov, identifier NCT02153112). On Day 1, children random...

Full description

Bibliographic Details
Main Authors: Pio López, Eduardo López-Medina, Xavier Sáez-Llorens, Rodrigo deAntonio, Taisei Masuda, Paul M. Mendelman, James Sherwood, Frank Baehner, Astrid Borkowski
Format: Article
Language:English
Published: Taylor & Francis Group 2023-01-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
norovirus
vaccine
children
immunogenicity
reactogenicity
virus-like particles
Online Access:http://dx.doi.org/10.1080/21645515.2023.2204787

Similar Items

Similar Items